glp-1 cancer risk The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and | Cancer and Metastasis Reviews Emerging Evidence Positions GLP-1 Receptor

10.1001/jama.2023.24945 [DOI] [PMC free article] [PubMed] 105.Aronne LJ, Horn DB, le Roux CW, et al

However, there are reasons to be optimistic about the future

In 2025, GLP-1RAs may gain FDA approval for new uses, including chronic kidney disease, certain types of heart failure, and liver disease

Thats the secret behind the weight loss that comes with this class of drugs

Recent Findings Originally developed for glycemic control in T2DM, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now being utilized for a range of additional diseases and conditions

doi: 10.1016/j.tice.2015.12.003 163 GebremedhnSSalilew-WondimDHoelkerMRingsFNeuhoffCTholenEet al